The PFP products protect medicines from contamination. They include a combination of a formulation without chemical preservatives, a pump system that filters or blocks the returning air, and an actuator that prevents bacterial ingress into the dispenser.
MWV says the five-fold mechanical protection system assures germ-free pump dosing to the patient. It includes non-return valves next to the orifice bore and in the metering chamber, and a filter element for contamination-free ventilation of the container, a locked actuator, and a sealed air path during storage.
The PFP T delivers volumes from 0.05mL to 0.14mL. Upside down and tamper-evident features are also available with the product.
‘We are expanding the range of preservative free pumps to meet consumer demand for preservative-free formulations,’ said Chris Hall, vice president and managing director, Medical Plastics Division, MWV Healthcare.
‘This technology does more than protect preservative free medicines from contamination, it is also suitable for use with other topical or dermal products where protecting the formulation and maintaining sterility is important, and necessary.’
MWV Healthcare expands preservative free pumps line
Manufacturing facility awarded certification for PFP spray systems
You may also like
Trending Articles
You may also like
Manufacturing
BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech
The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Regulatory
FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection
The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
Manufacturing
Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market
Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA